Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, placebo controlled, randomized multicenter Phase II Study evaluating Gemcitabine with or without Ramucirumab as II line treatment for advanced malignant pleural mesothelioma

Next Previous
Trial Profile

A double-blind, placebo controlled, randomized multicenter Phase II Study evaluating Gemcitabine with or without Ramucirumab as II line treatment for advanced malignant pleural mesothelioma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; Ramucirumab (Primary)
  • Indications Malignant-mesothelioma
  • Focus Therapeutic Use
  • Acronyms RAMES

Most Recent Events

  • 13 Mar 2025 Status changed from active, no longer recruiting to completed.
  • 06 Sep 2021 Results published in the Lancet Oncology
  • 21 Sep 2020 Primary endpoint has not been met. (Overall survival)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top